Diamedica Therapeutics (DMAC)
NASDAQ:DMAC
Want to see DMAC full AI Analyst Report?
DMAC Stock Chart & Stats
$6.85
-$0.24(-4.23%)
At close: 4:00 PM EST
$6.85
-$0.24(-4.23%)
Day’s Range― - ―
52-Week Range$3.48 - $10.42
Previous CloseN/A
Volume70.76K
Average Volume (3M)158.82K
Market Cap
$318.45M
Enterprise Value$313.79M
Total Cash (Recent Filing)$51.33M
Total Debt (Recent Filing)$212.00K
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Aug 12, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding53,883,347
10 Day Avg. Volume149,618
30 Day Avg. Volume158,825
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)6.66
Price to Sales (P/S)0.00
P/FCF Ratio-12.85
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.55
Forecast
1Y Price Target
$13.00Price Target Upside89.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Placental Safety And Maternal‑fetal BenefitDM199 does not cross the placenta and demonstrates strong vasodilation with early signs of improved placental perfusion, indicating potential to extend time to delivery and lower maternal‑fetal complications.
Rapid Blood Pressure EffectStatistically significant and clinically meaningful blood pressure reductions with rapid onset at higher doses suggest DM199 could provide immediate control of severe hypertension in preeclampsia.
Regulatory EngagementA pre‑IND meeting with the FDA to discuss Phase 2 plans for DM199 in preeclampsia reduces regulatory uncertainty and supports smoother trial initiation in the US.
Bears Say
Development Timeline And Cost PressureEnrollment shortfalls could lengthen development timelines and increase trial costs, raising potential financing needs and pressure on investor expectations.
Enrollment SlowdownLower than expected ongoing enrollment driven by changes in stroke referral patterns may slow trial progress and delay clinical milestones.
Referral Pattern DependenceDependence on transfers to large stroke center research sites creates vulnerability when referral patterns shift, reducing the pool of eligible patients for stroke studies.
Diamedica Therapeutics News
DMAC FAQ
What was Diamedica Therapeutics’s price range in the past 12 months?
Diamedica Therapeutics lowest stock price was $3.48 and its highest was $10.42 in the past 12 months.
What is Diamedica Therapeutics’s market cap?
Diamedica Therapeutics’s market cap is $318.45M.
When is Diamedica Therapeutics’s upcoming earnings report date?
Diamedica Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 78 days.
How were Diamedica Therapeutics’s earnings last quarter?
Diamedica Therapeutics released its earnings results on May 06, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.186 by -$0.004.
Is Diamedica Therapeutics overvalued?
According to Wall Street analysts Diamedica Therapeutics’s price is currently Undervalued.
Does Diamedica Therapeutics pay dividends?
Diamedica Therapeutics does not currently pay dividends.
What is Diamedica Therapeutics’s EPS estimate?
Diamedica Therapeutics’s EPS estimate is -0.2.
How many shares outstanding does Diamedica Therapeutics have?
Diamedica Therapeutics has 53,883,347 shares outstanding.
What happened to Diamedica Therapeutics’s price movement after its last earnings report?
Diamedica Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.186. Following the earnings report the stock price went up 0.153%.
Which hedge fund is a major shareholder of Diamedica Therapeutics?
Currently, no hedge funds are holding shares in DMAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Diamedica Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (89.78% Upside)
$13.00 (89.78% Upside)
Blogger Sentiment
Bullish
DMAC Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.92%
12-Months-Change
Fundamentals
Return on Equity
-77.09%
Trailing 12-Months
Asset Growth
36.70%
Trailing 12-Months
Company Description
Diamedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DMAC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress (stroke enrollment >70%, encouraging Phase II efficacy signals, Health Canada approval and active preeclampsia cohorts) and a clear pathway to multiple near-term clinical milestones through 2027. Financially, the company maintains a runway into 2027 but reported a quarter-over-quarter decline in cash, higher quarterly cash burn and materially higher R&D spend. Regulatory uncertainty in the U.S. (additional preclinical testing and an adverse rabbit study result) represents the primary risk to U.S. trial timelines. On balance, the clinical momentum and regulatory/operational achievements outweigh the financial and preclinical challenges at this stage.View all DMAC earnings summariesDMAC Stock 12 Month Forecast
Average Price Target
$13.00
▲(89.78% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Rocket Pharmaceuticals
―
Benitec Biopharma
―
Annexon Biosciences
―
Ownership Overview
43.45% Insiders
2.81% Mutual Funds
― Other Institutional Investors
50.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---